Hormonal
Long-acting GLP-1 receptor agonists (specifically Semaglutide 2.4 mg) and dual GIP/GLP-1 co-agonists (specifically Tirzepatide) produce clinically significant weight loss (12-18% average) in adults with obesity, significantly outperforming previous pharmacotherapies and rivaling bariatric surgery.
If you have obesity, older weight-loss drugs often fail to produce lasting results. Newer injectable medications like Semaglutide (Wegovy) and Tirzepatide (Mounjaro) work by mimicking gut hormones to reduce appetite and improve metabolism. In clinical trials, these drugs helped patients lose 12-18% of their body weight on average, with many losing over 20%. This level of weight loss is comparable to bariatric surgery. However, these are prescription medications with potential side effects like nausea, and they require weekly administration. Consult a doctor to see if you are a candidate.
Patients receiving long-acting glucagon-like peptide 1 (GLP1) agonist semaglutide achieve weight loss above 10 %. With tirzepatide, a co-agonist for GLP-1 and the gastric inhibitory polypeptide (GIP) receptor, more than 50 % of the patients even lose above 20 %, which rivals the efficacy of surgical interventions.
Why this rating
Based on Phase 3 clinical trials (STEP, SURPASS, SURMOUNT) cited in the text.
Source
GLP-1-Mimetika — wegweisend zur Behandlung von Diabetes und Adipositas
Kerstin Stemmer et al. · BIOspektrum · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →